

Study summary of the PRAETORIAN-COVID study: A double-blind, placebo-controlled randomized clinical trial with valsartan for PREvention of Acute rEspirATORY dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease

The PRAETORIAN-COVID study was initiated during the “first wave” of the COVID-19 pandemic in The Netherlands. The first patient was included on 17th April 2020. In the summer of 2020 enrollment decreased rapidly, due to low numbers of COVID-19 patients and many competing research activities at that time in The Netherlands. In August 2020, successful completion of the study with enrollment of about 650 patients was considered highly unlikely. Therefore, the study was prematurely halted. In total 23 patients were included in the study. Due to low number of participants, no definitive conclusions can be made based on this study alone regarding efficacy or safety of valsartan compared to placebo as a treatment for COVID-19 patients.